$AVLN

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corpora

Avalyn Pharma (AVLN) reported Q2 2026 results and said enrollment is complete for the global Phase 2b MIST trial of inhaled AP01 (pirfenidone) in progressive pulmonary fibrosis. The randomized, double-blind study enrolled 398 patients vs a 375 target, with 52-week safety and efficacy and topline data expected in H2 2027. Q2 R&D was $24.7M, net loss $28.9M, and cash $413.5M.

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory S

Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ck0001540171-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (this “ Amendment ”) is made and entered into as of June 29, 2026 (the “ Effective Date ”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation